AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00444535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: 10 mg/kg intravenous bevacizumab (every two weeks)
Study NCT03138213 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total laparoscopic pancreaticoduodenectomy
Description: Total laparoscopic pancreaticoduodenectomy
Study NCT03138213 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Open pancreaticoduodenectomy
Description: Open pancreaticoduodenectomy
Study NCT02964481 — intervention group
Intervention type: GENETIC
Intervention: Whole exome sequencing
Description: DNA sequencing of protein coding sections of all genes
Study NCT03718637 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Smith & Nephew Bioinductive Implant
Description: A bioinductive implant that is supposed to foster healthy tendon regrowth after surgery.
Study NCT03718637 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lateral Epicondylectomy
Description: This procedure is the standard of care for lateral epicondylitis patients who fail conservative treatment options.
Study NCT03718637 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lateral Epicondylectomy
Description: This procedure is the standard of care for lateral epicondylitis patients who fail conservative treatment options.
Study NCT03718637 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound Imaging
Description: An ultrasound will be performed on each patient both preoperatively and at 6 months.
Study NCT03718637 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Ultrasound Imaging
Description: An ultrasound will be performed on each patient both preoperatively and at 6 months.
Study NCT01832064 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mailed Chronic Disease Self-Management Program
Description: materials are mailed to participants
Study NCT02498197 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Participatory Intervention
Study NCT02498197 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Study NCT01978132 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: forearm ischemia and reperfusion
Description: both arms will be subjected to 20 minutes of forearm ischemia and 20 minutes of reperfusion.
Study NCT01978132 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: forearm ischemia and reperfusion
Description: both arms will be subjected to 20 minutes of forearm ischemia and 20 minutes of reperfusion.
Study NCT00413582 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epidural Analgesia
Description: Upon arrival to the operating room, patients will have a thoracic epidural (T 6-9) placed while in the sitting position. All epidural catheters will be inserted 3-5 cm within the epidural space and will be placed by attending anesthesiologists. Patients will receive midazolam 0.025 - 0.05 mg/kg IV (max 5mg) and/or fentanyl 0.5 - 2 mcg/kg IV for comfort during the procedure. Once the epidural is placed, the patient will be positioned for surgery. The epidural catheter will be initially bolused with 0.3ml/kg of ropivacaine 0.10% (max 10 ml), fentanyl 1 - 1.2 mcg/kg and clonidine 1.8 - 2mcg/kg. An infusion of ropivacaine 0.10%, fentanyl 2mcg/ml and clonidine 1.5mcg/ml will be initiated immediately at the rate of 0.3ml/kg/hr (max 10ml/hr). Intraoperatively, patients will receive intravenous fentanyl if indicated.
Study NCT00413582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patient-Controlled IV Analgesia
Description: In the PCA arm, patients will receive fentanyl (3-6 mcg/kg) at anesthesia induction. Additional fentanyl may be administered intraoperatively as indicated. Patients who are > 35 Kg. (in keeping with current FDA approved labeling) will receive a clonidine 0.1 mg/day transdermal patch to the deltoid immediately after induction of anesthesia. Subjects in the epidural arm also receive clonidine. Upon arrival to the post anesthesia care unit, patients will be placed on a patient controlled analgesic (PCA) pump (hydromorphone: loading dose if needed; 5-6 mcg/kg continuous infusion; 5-6 mcg/kg six minute demand dose). An additional hydromorphone dose (8mcg/kg) will be available every 2 hours for pain scores of > 4/10 throughout the duration of PCA use.
Study NCT00762255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Vorinostat, Bevacizumab and Irinotecan Study. Determine maximum tolerated dose for treatment.
Study NCT00762255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Vorinostat, Bevacizumab and Irinotecan Study. Determine maximum tolerated dose for treatment.
Study NCT00762255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Vorinostat, Bevacizumab and Irinotecan Study. Determine maximum tolerated dose for treatment.
Study NCT01774760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-EF5
Study NCT01774760 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pretreatment PET/CT-scan (performed two times)
Study NCT04396808 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Decipher
Description: The Decipher test (GenomeDx Biosciences) is a genomic test that will be performed on prostate biopsy tissue. Results will be provided to the patient and physician prior to making a treatment decision.
Study NCT04396808 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Prolaris
Description: The Prolaris test (Myriad Genetics, Inc.) is a genomic test that will be performed on prostate biopsy tissue. Results will be provided to the patient and physician prior to making a treatment decision.
Study NCT04396808 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Oncotype Dx Genomic Prostate Score (GPS)
Description: The Oncotype Dx GPS test (Exact Sciences corp.) is a genomic test that will be performed on prostate biopsy tissue. Results will be provided to the patient and physician prior to making a treatment decision.
Study NCT04396808 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care (askMUSIC score)
Description: AskMUSIC is a risk calculator based on standard clinical and pathologic variables (https://ask.musicurology.com/) and is generally included as part of routine clinical care.
Study NCT04252690 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MOBIDERM® autofit : auto-adjustable compression stocking
Description: The experimental protocol will require 2 visits during usual reduction phase performed at the hospital (5 days of hospitalization).~Visit 1 will be performed the first day of hospitalization and will consist of inclusion visit and some evaluations (lymphoscintigraphy, edema volume, cutaneous characteristics).~Between visit 1 (D1) and visit 2 (D3), patients will wear Mobiderm Autofit continually.~Visit 2 will be performed the third day of hospitalization and will consist of evaluations (lymphoscintigraphy, edema volume, cutaneous characteristics, satisfaction survey).
Study NCT00989482 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer kiosk Education
Description: computerized patient education; guidelines for physicians
Study NCT03729167 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Scaling and root planing
Description: Non-surgical instrumentation will be performed with specific instruments prior to treatment planned extraction by another provider.
Study NCT03065855 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early removal group
Description: Participants assigned to the experimental arm will have their urethral catheters removed at 2 days after after laparoscopic anterior resection of the rectum.
Study NCT03065855 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Normal removal group
Description: Participants assigned to the control group will have their urethral catheters removed at 7days following surgery, as is standard practice in our institution.
Study NCT02069639 — intervention group
Intervention type: OTHER
Intervention: no treatment
Study NCT01600300 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham Tesmac device
Description: Treatment with inactivated Tesmac device on the same schedule as the group treated with the active Tesmac device.
Study NCT04275388 — intervention group
Intervention type: DRUG
Intervention: Xiyanping injection
Description: Xiyanping injection, 10-20ml daily, Qd, the maximum daily does not exceed 500mg (20mL) + Lopinavir tablet /Ritonavir tablet or Alpha-interferon nebulization or Abidor Hydrochloride,
Study NCT04275388 — intervention group
Intervention type: DRUG
Intervention: Lopinavir / ritonavir, alpha-interferon nebulization,Abidor Hydrochloride
Description: Lopinavir / ritonavir tablets, 2 times a day, 2 tablets at a time; alpha-interferon nebulization;Abidor Hydrochloride
Study NCT02311543 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TachoSil® patches
Description: TachoSil® is a sterile, ready-to-use, absorbable surgical patch and consists of an equine collagen sponge coated with human fibrinogen and human thrombin.
Study NCT03751319 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CGA
Description: Comprehensive Geriatric Assessment
Study NCT00999245 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: High Demand / Low Infusion
Description: HDLI dosing plan will administer either morphine or hydromorphone using PCA. Dosing will be based on body weight.
Study NCT00999245 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: PCA Dosing Plan
Description: LDHI dosing plan will administer either morphine ot hydromorphone using PCA. Dosing will be based on body weight.
Study NCT03870737 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active TNS
Description: Participants will receive 4-weeks nightly treatment with active TNS. Positive responders will be invited to participate in 12-month open-extension study.
Study NCT00759174 — intervention group
Intervention type: DRUG
Intervention: No intervention
Description: No intervention occurs in this observational study.
Study NCT00709735 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propranolol
Description: 0.67 mg/kg short-acting propranolol combined with 1 mg/kg long-acting propranolol
Study NCT00709735 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: 0.67 mg/kg short-acting propranolol combined with 1 mg/kg long-acting propranolol
Study NCT00709735 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo (matching propranolol) short-acting and long-acting capsules
Study NCT00709735 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo (matching propranolol) short-acting and long-acting capsules
Study NCT01532011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Dose escalation group starting dose: 75 mg by mouth daily for a 28 day cycle.~Dose expansion group starting dose: Maximum tolerated dose (MTD) from dose escalation group.
Study NCT01532011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pralatrexate
Description: Dose escalation group starting dose: 15 mg/m2 by vein on days 1, 8, and 15 of a 28 day cycle.~Dose expansion group starting dose: Maximum tolerated dose (MTD) from dose escalation group.
Study NCT03800186 — intervention group
Intervention type: OTHER
Intervention: Proximal type A
Description: Patients with fracture of proximal type A
Study NCT03800186 — intervention group
Intervention type: OTHER
Intervention: Proximal type B
Description: Patients with fracture of proximal type B
Study NCT03800186 — intervention group
Intervention type: OTHER
Intervention: Proximal type C
Description: Patients with fracture of proximal type C
Study NCT03800186 — intervention group
Intervention type: OTHER
Intervention: femoral shaft
Description: Patients with fracture of femoral shaft
Study NCT03800186 — intervention group
Intervention type: OTHER
Intervention: distal femur
Description: Patients with fracture of distal femur
Study NCT04861415 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Sterotactic Body Radiotherapy
Description: Hypofractionated stereotactic radiation treatment.
Study NCT04861415 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Conventionally Fractionated Radiation
Description: External beam radiation therapy treatment
Study NCT01938092 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diazepam
Study NCT01938092 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00419991 — intervention group
Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Tigecycline
Description: All patients will receive tigecycline infusions approximately every 12 or 24 hours. The usual regimen of tigecycline is (an initial intravenous (IV) dose of 100 mg followed by 50 mg approximately every 12 hours). Patients with severe hepatic dysfunction may, at the investigator's discretion with CPL Associates approval (call enrollment hotline) may be given a total daily dose of 50 mg (one 50 mg dose or 25 mg approximately every 12 hours). Tigecycline infusions will be administered over approximately 30 minutes in 100 mL of normal saline.
Study NCT01294176 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lipoic Acid
Description: Lipoic acid will be administered orally, in two 600mg capsules, for a total 1200mg dose. The dose will be administered daily for a 6-week treatment period.
Study NCT01294176 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lipoic Acid
Description: Lipoic acid will be administered orally, in two 600mg capsules, for a total 1200mg dose. The dose will be administered daily for a 6-week treatment period.
Study NCT01436513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Premarin reference tablet (fasted)
Description: Premarin reference tablet, single dose, fasted conditions
Study NCT01436513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Premarin new tablet (fasted)
Description: Premarin new tablet, single dose, fasted conditions
Study NCT01436513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Premarin reference tablet (fed)
Description: Premarin reference tablet, single dose, fed conditions
Study NCT01436513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Premarin new tablet (fed)
Description: Premarin new tablet, single dose, fed conditions
Study NCT01408511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mapracorat
Description: Application of the investigational product on the affected skin areas
Study NCT00985504 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: 60-120 milligrams (mg) taken once daily (QD) by mouth (po) for 8 weeks; with option for additional 2 weeks.
Study NCT00985504 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: 10-20 mg taken QD po for 8 weeks; with option for additional 2 weeks.
Study NCT04651933 — intervention group
Intervention type: GENETIC
Intervention: Homologous recombination deficiency model
Description: A homologous recombination deficiency (HRD) scoring model based on loss of heterozygosity (LOH)
Study NCT01882985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Given IV
Study NCT01882985 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lycopene
Description: Given PO
Study NCT03359616 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transanally curable surgical resection
Description: Transanally, the rectal cancer will be mobilized with oncological principle of total mesorectal excision
Study NCT03359616 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic total mesorectal excision
Description: Conventionally by laparoscopic surgery, the rectal cancer will be mobilized with oncological principle of total mesorectal excision
Study NCT04622605 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trabecular bypass and Schlemm's canal stent
Description: ab interno Microstent placement after cataract surgery
Study NCT00925704 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcitriol
Description: Calcitriol (1.0 microgram) single dose at lunch administered on Day 1 of the study period.
Study NCT00925704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanthanum carbonate + Calcitriol
Description: Lanthanum carbonate (1000 mg three times daily with meals for one day) + calcitriol (1.0 microgram) single dose at lunch administered on Day 1 of the study period.
Study NCT00925704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevelamer carbonate + Calcitriol
Description: Sevelamer carbonate (2400 mg three times daily with meals for one day) + calcitriol (1.0 microgram) single dose at lunch administered on Day 1 of the study period.
Study NCT03837054 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Blood collection and Micronuclei assay on binucleate lymphocytes in culture
Description: The activity of the oncology Department of the North Hospital ensures the quick and easy recruitment of 30 patients over the 10-month inclusion period. The collection of samples will be done in a forward-looking manner during chemotherapy and at different times. The patients will have 4 blood samples of 10 mL carried out during their chemotherapy with a sampling at T0 (before the initiation of chemotherapy), then to T1 (after the first 3 cures), to T2 (after the 6th cure) and to T3 is 5 weeks after the end of the chemo And before the onset of radiation therapy. The samples will be carried out within the Medical Oncology Department of the hospital Nord of Marseille.~We will also perform micronuclei testing on Binucleate lymphocytes in culture. The lymphocyte Micronuclei test reveals structure and number chromosomal damage and allows to reveal clastogenic or eugènes exposures.
Study NCT02280837 — intervention group
Intervention type: OTHER
Intervention: Determination of plasma GLP-1 level
Description: Determination of GLP-1 level in samples of oral glucose tolerance tests
Study NCT02850146 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-AV-1451
Study NCT01671228 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decision Aid
Description: The Yorkshire Dialysis Decision Aid (YoDDA) resource in web and paper format
Study NCT01671228 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decision aid + patient stories
Description: The Yorkshire dialysis decision aid (YoDDA) plus a set of narratives provided by patients on the treatment options (home and hospital haemodialysis; continuous ambulatory and automated peritoneal dialysis
Study NCT01671228 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decision Aid + values task
Description: The Yorkshire Dialysis decision aid (YoDDA) plus a set of questions to help patients explore what aspects of their life important to them about this decision (values clarification)
Study NCT01890122 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alogliptin
Description: Alogliptin tablets
Study NCT01890122 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin HCl
Description: Metformin HCl capsules
Study NCT01890122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alogliptin and Metformin Fixed-Dose Combination (FDC)
Description: Alogliptin and metformin FDC tablets
Study NCT01890122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alogliptin Placebo
Description: Alogliptin placebo-matching tablets
Study NCT01890122 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alogliptin Placebo
Description: Alogliptin placebo-matching tablets
Study NCT01890122 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Alogliptin Placebo
Description: Alogliptin placebo-matching tablets
Study NCT01890122 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin Placebo
Description: Metformin placebo-matching capsules
Study NCT01890122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin Placebo
Description: Metformin placebo-matching capsules
Study NCT01890122 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin Placebo
Description: Metformin placebo-matching capsules
Study NCT01210768 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin+Cyclophosphamide
Description: Cyclophosphamide 600 mg/m2 infusion followed by epirubicin 90 mg/m2 infusion on Day 1 in each 21-day treatment cycle. Treatment will be repeated for 4 cycles in the EC arm.
Study NCT01210768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liposomal-doxorubicin+Cyclophosphamide
Description: Cyclophosphamide 600 mg/m2 infusion followed by pegylated liposomal-doxorubicin 37.5mg/m2 infusion on Day 1 in each 21-day treatment cycle. Treatment will be repeated for 5 cycles in the LC arm.
Study NCT00616967 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carboplatin
Description: Given IV
Study NCT00616967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV
Study NCT00616967 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel albumin-stabilized nanoparticle formulation
Description: Given IV
Study NCT00616967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel albumin-stabilized nanoparticle formulation
Description: Given IV
Study NCT00616967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Description: Given orally
Study NCT00616967 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Given orally
Study NCT01229228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen Test
Description: 200-mg single dose